Pharmaceutical intermediates

Cangrelor Tetrasodium Intermediates

2 pharmaceutical intermediates for Cangrelor Tetrasodium. Indication: Coronary thrombosis; Myocardial infarction; Thrombosis; Acute coronary syndrome.

提交项目 All intermediates

About Cangrelor Tetrasodium

Originator: The Medicines Company
Indication: Coronary thrombosis; Myocardial infarction; Thrombosis; Acute coronary syndrome
Approved Date: 06/22/2015
DS/DP: 05/13/2029

Available intermediates

2 intermediates currently listed for Cangrelor Tetrasodium. Request specifications, documentation or a quotation for any item below.

Cangrelor Tetrasodium intermediates
Product Name	CAS No.	Molecular Formula	Physical Properties
(2R,3S,4R,5R)-2-(hydroxyMethyl)-5-(6-((2-(Methylthio)ethyl)aMino)-2-((3,3,3-trifluoropropyl)thio)-9H-purin-9-yl)tetrahydrofuran-3,4-diol	163706-58-9	/	/
Phosphonic acid, P,P'-(dichloromethylene)bis-, compd. with N,N-dibutyl-1-butanamine (1:1)	163706-61-4	/	/

Other programs under C

Cabozantinib S-malate Calcipotriol Calcitriol Camlipixant Canagliflozin Capivasertib Capmatinib Hydrochloride Carfilzomib

Building toward Cangrelor Tetrasodium?

Tell us the step you need covered and the specification you are filing against. We will confirm supply, documentation and lead time.

提交项目联系团队

我们能如何帮助您？

获取最新活动与法规动态洞察

直接发送到您的邮箱

在此获取行业洞察与 Unibest 动态

联系我们 →